Formulation of ternary complexes of glyburide with hydroxypropyl-β- cyclodextrin and other solubilizing agents and their effect on release behavior of glyburide in aqueous and buffered media at different agitation speeds

Drug Development and Industrial Pharmacy

Volumn 38, Issue 11, 2012, Pages 1328-1336

  Singh, Sachin Kumar ^a,b   Srinivasan, K K ^c   Singare, Dhananjay S ^d   Gowthamarajan, K ^e   Prakash, Dev ^a  

^a KARPAGAM UNIVERSITY   (India)

^b BHARATHI COLLEGE OF PHARMACY   (India)

^c MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^d DR REDDY'S LABORATORIES LTD   (India)

^e JSS COLLEGE OF PHARMACY   (India)

Author keywords

Discriminatory; DSC; Glyburide; HP Cd; Ternary system; X ray analysis

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ARGININE; DODECYL SULFATE SODIUM; GLIBENCLAMIDE; LACTOSE; POLOXAMER; POVIDONE; SOLUBILIZER;

ARTICLE; DISPERSION; DRUG FORMULATION; DRUG SOLUBILITY; ENCAPSULATION; THERMOGRAPHY; X RAY POWDER DIFFRACTION;

BETA-CYCLODEXTRINS; BUFFERS; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG COMPOUNDING; GLYBURIDE; HYDROGEN-ION CONCENTRATION; HYPOGLYCEMIC AGENTS; KINETICS; PHARMACEUTIC AIDS; PHASE TRANSITION; SOLUBILITY; STRESS, MECHANICAL; TABLETS; TIME FACTORS; WATER; X-RAY DIFFRACTION;

EID: 84866888430     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.650645     Document Type: Article

References (39)

1. Amidon GL, Lennernäs H, Shah VP, Crison Jr. (1995). A theoretical basis for a biopharmaceutic drug classifcation: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413-420.
2. Jinno J, Oh D, Crison JR, Amidon GL. (2000). Dissolution of ionizable water-insoluble drugs: the combined efect of pH and surfactant. J Pharm Sci, 89:268-274.
3. Hoener B, Benet LZ, Banker GS, Rhodes CT. New York: Modern Pharmaceutics, Marcel Dekker, 1990:143.
4. Jorgensen ED, Bhagwat. (1998). Pharm Sci Technol Today, 1:128-135.
5. Kapsi SG, Ayres JW. (2001). Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. Int J Pharm, 229:193-203.
6. Aguiar AJ, Zelmer AJ, Kinkel AW. (1979). Deagglomeration behavior of relatively insoluble benzoic acid and its sodium salt. J Pharm Sci, 56:1243-125.
7. Finholt P, Solvang S. (1968). Dissolution kinetics of drugs in human gastric juice-the role of surface tension. J Pharm Sci, 57:1322-1326.
8. Lin SL, Menig J, Lachman L. (1968). Interdependence of physiological surfactant and drug particle size on the dissolution behavior of water insoluble drugs. J Pharm Sci, 57:2143-2148.
9. Duchêne D. (1987). In: Cyclodextrin and their Industrial Uses, Ed. de Santè, Paris.
10. Szejli J. (1988). Cyclodextrin Technology. Dordrecht: Kluwer Academic Publishers.
11. Uekama K, Hirayama F, Irie T. (1998). Cyclodextrin drug carrier systems. Chem Rev, 98:2045-2076.
12. Loftsson T, Brewster ME. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci, 85:1017-1025.
13. Loftsson T, Fridriksdóttir H, Sigurdardóttir AM, Ueda H. (1994). The efect of water-soluble polymers on drug-cyclodextrin com-plexation. Int J Pharm, 110:169-177.
14. Ganzerli G, Van SL, Verschuren E, Ludwig A. (1996). Infuence of β-cyclodextrin and various polysaccharides on the solubility of fuorescein and on the rheological and mucoadhesive properties of ophtalmic solutions. Pharmazie, 51:357-362.
15. Loftsson T, Gudmundsdóttir TK, Fridriksdóttir F. (1996). The infuence of water-soluble polymers and pH on hydroxypropyl-cyclodextrin complexation of drugs. Drug Dev Ind Pharm, 22:401-405.
16. Redenti E, Szente L, Szejtli J. (2000). Drug/cyclodextrin/hydroxy acid multicomponent systems. Properties and pharmaceutical applications. J Pharm Sci, 89:1-8.
17. Mura P, Faucci MT, Manderioli A, Bramanti G. (2001). Multicomponent systems of econazole with hydroxyacids and cyclodextrins. J Incl Phen, 39:131-138.
18. Redenti E, Szente L, Szejtli J. (2001). Cyclodextrin complexes of salts of acidic drugs. Termodynamic properties, structural features, and pharmaceutical applications. J Pharm Sci, 90:979-986.
19. Vikmon M, Kolbe I, Szejtli J, Redenti E, Ventura P. (1999). Preparation and characterization of piroxicam alkali-salt γ-cyclodextrin complexes. Proceedings 9th Intern. Symp. Cyclodextrins. Dordrecht: Kluwer Academic Publishers, pp 281-284.
20. Piel G, Pirotte B, Delneuville I, Neven P, Llabres G, Delarge J et al. (1997). Study of the infuence of both cyclodextrins and L-lysine on the aqueous solubility of nimesulide; isolation and characterization of nimesulide-L-lysine- cyclodextrin complexes. J Pharm Sci, 86:475-480.
21. Mura P, Faucci MT, Bettinetti GP. (2001). The efect of polyvinyl pyrrolidone on hydroxypropyl-β-cyclodextrin complexation with naproxen. Eur J Pharm Sci, 13:187-194.
22. Zerrouk N, Corti G, Ancillotti S, Maestrelli F, Cirri M, Mura P. (2006). Infuence of cyclodextrins and chitosan, separately or in combination, on glyburide solubility and permeability. Eur J Pharm Biopharm, 62:241-246.
23. Klein S, Wempe MF, Zoeller T, Buchanan NL, Lambert JL, Ramsey MG et al. (2009). Improving glyburide solubility and dissolution by complexation with hydroxybutenyl-β-cyclodextrin. J Pharm Pharmacol, 61:23-30.
24. Klein S, Zoeller T. Improving Solubility and Dissolution of Glyburide: Solid Dispersions, Binary and Ternary Cyclodextrin Complexes. AAPS 2009; AAPS Annual Meeting and Exposition 11/7/2009-11/12/200.
25. Higuchi T, Connors K. (1965). Phase-solubility techniques. Adv Anal Chem Instrum, 4:117-212.
26. Costa P. (2001). An alternative method to the evaluation of similarity factor in dissolution testing. Int J Pharm, 220:77-83.
27. Morris KR, Fakes MG, Takur AB, Newman AW, Singh AK, Venit JJ, Spagnuolo CJ, Serajuddin ATM. (1994). An integrated approach to the selection of optimal salt form for a new drug candidate. Int J Pharm, 105:209-217.
28. Berge SM, Bighley LD, Monkhouse DC. (1977). Pharmaceutical salts. J Pharm Sci, 66:1-19.
29. Laveneziana D, Speranza R, Raulli P, Paredi G.(1996). Ibuprofen-arginine in the management of pain. Clin Drug Invest, 11:1-7.
30. Krishnamoorthy R, Mitra AK. (1996). Complexation of weak acids and bases with cyclodextrins: efects of substrate ionization on the estimation and interpretation of association constants. Int J Pharm Adv, 1:330-343.
31. Loftsson T, Olafsdottir B, Frioriksdottir H, Jònsdòttir S. (1993). Cyclodextrin complexation of NSAIDs: physicochemical characteristics. Eur J Pharm Sci, 1:95-101.
32. Steiner T, Koellner G, Gessler K, Saenger W. (1995). Isostructural replacement of a N-H*O by a C-H*O hydrogen bond in complex stabilisation: crystal structures of β-cyclodextrin complexed with diethanolamine and with pentane-1,5-diol. J Chem Soc Chem Commun, 511-512.
33. United States Pharmacopeia and National Formulary USP 30-NF 25. The United States Pharmacopeial Convention, Inc.: Rockville, MD, 2007; pp 3179-3180.
34. Leeson JL. (2000). Some Observations on 'Rethinking the Use of Water as Dissolution Medium' Dissolution Technol, 7:16-17.
35. Mura P, Adragna E, Rabasco AM, Moyano JR, Pérez-Martìnez JI, Arias MJ et al. (1999). Efects of the host cavity size and the preparation method on the physicochemical properties of ibuproxam-cyclodextrin systems. Drug Dev Ind Pharm, 25:279-287.
36. Bayomi MA, Abanumay KA, Al-Angary AA. (2002). Efect of inclusion complexation with cyclodextrins on photostability of nifedipine in solid state. Int J Pharm, 243:107-117.
37. Manosroi J, Apriyani MG, Foe K, Manosroi A. (2005). Enhancement of the release of azelaic acid through the synthetic membranes by inclusion complex formation with hydroxypropyl-β-cyclodextrin. Int J Pharm, 293:235-240.
38. Ribeiro LS, Ferreira DC, Veiga FJ. (2003). Physicochemical investigation of the efects of water-soluble polymers on vinpocetine complexation with beta-cyclodextrin and its sulfobutyl ether derivative in solution and solid state. Eur J Pharm Sci, 20:253-266.
39. Williams RO 3rd, Mahaguna V, Sriwongjanya M. (1998). Characterization of an inclusion complex of cholesterol and hydroxypropyl-β-cyclodextrin. Eur J Pharm Biopharm 46: 355-360.